Immune checkpoint inhibitors (ICIs) have revolutionized the treatment of cancer. ICIs have a unique side effect profile, generally caused by inflammatory tissue damage, with clinical features similar to autoimmune conditions. Acute kidney injury from ICIs has been well studied; incidence ranges from 1% to 5%, with higher incidence when combination ICI therapies are used. Although the overall reported incidence of ICI-associated glomerulonephritis is less than 1%, vasculitis is the most commonly reported ICI-related glomerulonephritis. Other biopsy findings include thrombotic microangiopathy, focal segmental glomerulosclerosis, minimal change disease, and IgA nephropathy with secondary amyloidosis. We report a case in which a woman previously treated with the PD-L1 inhibitor durvalumab for locally advanced non-small cell lung cancer with pre-existing antineutrophil cytoplasmic (anti-PR3) antibody who later developed multi-organ vasculitis after ICI exposure, which was successfully treated with rituximab, with continued cancer remission for 3 years.
CITATION STYLE
Qureshi, S., Arani, N., Parvathareddy, V., Tchakarov, A., Abdelrahim, M., Suarez-Almazor, M., … Abudayyeh, A. (2023). Case Report: Immune checkpoint inhibitor–induced multiorgan vasculitis successfully treated with rituximab. Frontiers in Nephrology, 3. https://doi.org/10.3389/fneph.2023.1168614
Mendeley helps you to discover research relevant for your work.